Class A Common Stock, par value $0.0001 per share
- Symbol
- SKIN
- Exchange
- NASDAQ
- Classification
- COMMON
Current Report · Items 1.02, 7.01 · 8-K
SkinHealth Systems Inc.
Termination of a Material Definitive Agreement · Regulation FD Disclosure
Item 1.02. Termination of a Material Definitive Agreement. On September 30, 2026, the remaining outstanding aggregate principal amount of the 1.25% Convertible Senior Notes due 2026 (the “Notes”) issued by SkinHealth Systems Inc. (the “Company”), pursuant to the Indenture, dated as of September 14, 2021 (the “Indenture”), by and among the Company and U.S.…
Company context
SkinHealth Systems (NASDAQ: SKIN) is a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions designed to help consumers achieve superior skin health and support the success of providers. Anchored by Hydrafacial™, a leading and widely requested professional skincare treatment, and supported by complementary offerings including SkinStylus™ microneedling and HydraScalp™ with Keravive™, SkinHealth Systems combines advanced device technology, proprietary consumables, and clinical validation to deliver trusted treatment experiences
Current securities
Historical securities (6)
SKINNASDAQ · EQUITY · Historical · closed May 5, 2021SKINNASDAQ · EQUITY · Historical · closed Oct 19, 2026SKINWNASDAQ · WARRANT · Historical · closed Nov 3, 2021VSPRNASDAQ · EQUITY · Historical · closed May 5, 2021VSPRUNASDAQ · UNIT · Historical · closed May 5, 2021VSPRWNASDAQ · WARRANT · Historical · closed May 5, 2021
Recent company filings
- Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD DisclosureOct 14, 2026
- Submission of Matters to a Vote of Security HoldersSep 28, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 10, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsAug 14, 2026
- 4 filingAug 12, 2026
Registered securities in this filing
SkinHealth Systems Inc. · 8-K · Filed 2026-10-06
Disclosure sections
Item 1.02Item 1.02 - Termination of Material Agreement
Item 1.02. Termination of a Material Definitive Agreement.
On September 30, 2026, the remaining outstanding aggregate principal amount of the 1.25% Convertible Senior Notes due 2026 (the “Notes”) issued by SkinHealth Systems Inc. (the “Company”), pursuant to the Indenture, dated as of September 14, 2021 (the “Indenture”), by and among the Company and U.S. Bank National Association, as trustee (the “Trustee”), was repaid in full by the Company, together with accrued and unpaid interest thereon.
In conjunction with the full and final repayment of the Notes, the Indenture was satisfied and discharged in accordance with its terms and the Trustee acknowledged such satisfaction and discharge. As a result of the satisfaction and discharge of the Indenture, the Company was released from its remaining obligations under the Indenture except those provisions of the Indenture that, by their terms, survive the satisfaction and discharge of the Indenture.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
On September 30, 2026, the Company retired the Notes in accordance with their terms. The Company repaid the remaining outstanding aggregate principal amount of $103,235,000 together with accrued and unpaid interest thereon of $645,218.75. The Notes were issued on September 14, 2021 and were set to mature on October 1, 2026.
The information set forth under Item 7.01 of this Current Report on Form 8-K (the “Current Report”) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report shall not be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.